Logo image
Back
A Research and Development (R&D) Roadmap for Broadly Protective Coronavirus Vaccines: A Pandemic Preparedness Strategy
Journal article   Open access   Peer reviewed

A Research and Development (R&D) Roadmap for Broadly Protective Coronavirus Vaccines: A Pandemic Preparedness Strategy

Kristine A. Moore, Tabitha Leighton, Julia T. Ostrowsky, Cory J. Anderson, Richard N. Danila, Angela K. Ulrich, Eve M. Lackritz, Angela J. Mehr, Ralph S. Baric, Norman W. Baylor, …
Vaccine, Vol.41(13), pp.2101-2112
03/2023
DOI: 10.1016/j.vaccine.2023.02.032
PMCID: PMC9941884
PMID: 36870874
url
https://doi.org/10.1016/j.vaccine.2023.02.032View
Published (Version of record) Open Access

Abstract

Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 22 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.
 broadly protective coronavirus vaccines C-TAP, COVID-19 Technology Access Pool CEPI, Coalition for Epidemic Preparedness Innovations CHIM, controlled human infection model CIDRAP, Center for Infectious Disease Research and Policy CoP, Correlate of protection coronavirus coronavirus vaccines COVID-19 vaccines CVR, Coronavirus Vaccines Research and Development Roadmap DNA, deoxyribonucleic acid DPP4, dipeptidyl peptidase 4 Fc-R, Fc receptor FVVA, full value of vaccine assessment GISRS, Global Influenza Surveillance and Response System hACE2, human angiotensin converting enzyme-2 HICs, high-income countries LMICs, low- and middle-income countries MERS-CoV, Middle East respiratory syndrome coronavirus pandemic preparedness PPC, preferred product characteristics R&D, Research and Development RBD, receptor-binding domain Review RNA, ribonucleic acid roadmap SARS-CoV, severe acute respiratory syndrome coronavirus SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 TPP, target product profile US Food and Drug Administration, US FDA vaccine research WHO, World Health Organization

Details

Metrics

33 Record Views
21 Times Cited - Web of Science
Logo image